Next-Generation Bispecific Antibodies for Combinatorial T-cell activation in Cancer Immunotherapy

• Unité de recherche: INNOSUISSE
• Numéro de projet: 129.370 IP-LS
• Titre du projet anglais: Next-Generation Bispecific Antibodies for Combinatorial T-cell activation in Cancer Immunotherapy

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

We will develop next-generation CD3 bispecific antibodies with delivery of costimulatory signals to enhance T-cell function and persistence in therapeutically challenging malignancies like colorectal cancer and acute myeloid leukemia, aiming for improved safety, durability, and efficacy.